Merus N.V. (MRUS) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 210 transactions totaling $7.8B, demonstrating a bullish sentiment with $7.6B in net insider flow. The most recent transaction on Dec 29, 2025 involved a purchase of 75,867,199 shares valued at $7.4B.
No significant insider buying has been recorded for MRUS in the recent period.
No significant insider selling has been recorded for MRUS in the recent period.
Based on recent SEC filings, insider sentiment for MRUS is bullish with an Insider Alignment Score of 99/100 and a net flow of $7.6B. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Merus N.V. (MRUS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading MRUS stock, having executed 210 transactions in the past 90 days. The most active insider is A/s Genmab (Executive), who has made 11 transactions totaling $7.6B.
Get notified when executives and directors at MRUS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 29, 2025 | Genmab A/s | Executive | Purchase | 75,867,199 | $97.00 | $7.4B | Large |
| Dec 29, 2025 | Genmab A/s | Executive | Purchase | 1,052,806 | $97.00 | $102.1M | Large |
| Dec 26, 2025 | Genmab A/s | Executive | Purchase | 142,610 | $97.00 | $13.8M | Large |
| Dec 26, 2025 | Genmab A/s | Executive | Purchase | 2,978 | $97.00 | $288.9K | |
| Dec 24, 2025 | Genmab A/s | Executive | Purchase | 96,082 | $97.00 | $9.3M | Large |
| Dec 23, 2025 | Genmab A/s | Executive | Purchase | 561,042 | $97.00 | $54.4M | Large |
| Dec 22, 2025 | Genmab A/s | Executive | Purchase | 15,710 | $97.00 | $1.5M | Large |
| Dec 19, 2025 | Genmab A/s | Executive | Purchase | 66,264 | $97.00 | $6.4M | Large |
| Dec 18, 2025 | Genmab A/s | Executive | Purchase | 212,177 | $97.00 | $20.6M | Large |
| Dec 17, 2025 | Genmab A/s | Executive | Purchase | 150,795 | $97.00 | $14.6M | Large |
| Dec 16, 2025 | Genmab A/s | Executive | Purchase | 120,752 | $97.00 | $11.7M | Large |
| Dec 12, 2025 | T. Iwicki Mark | Executive | Tender | 73,576 | $97.00 | $7.1M | Large |
| Dec 12, 2025 | Shuman Harry | Executive | Tender | 11,002 | $97.00 | $1.1M | Large |
| Dec 12, 2025 | Ante Lundberg Sven | Executive | Tender | 16,372 | $97.00 | $1.6M | Large |
| Dec 12, 2025 | Ante Lundberg Sven | Executive | Tender | 30,297 | $97.00 | $2.9M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 49 | $7.7B | 98.5% |
Sale(S) | 43 | $88.9M | 1.1% |
Tender(U) | 8 | $16.3M | 0.2% |
Award(A) | 1 | $8.7M | 0.1% |
Exercise(M) | 97 | $6.0M | 0.1% |
Gift(G) | 12 | $0 | 0.0% |
Insiders at Merus N.V. are accumulating shares at an accelerated pace. With 19 insiders making 210 transactions totaling $7.7B in purchases versus $88.9M in sales, the net buying activity of $7.6B signals strong executive confidence. A/s Genmab (Executive) leads the buying activity with $7.6B in transactions across all time.